Analysts Set argenx SE (NASDAQ:ARGX) Target Price at $639.78

Shares of argenx SE (NASDAQ:ARGX - Get Free Report) have received a consensus rating of "Moderate Buy" from the twenty-two analysts that are presently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, eighteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $639.78.

ARGX has been the topic of several research reports. Baird R W downgraded shares of argenx from a "strong-buy" rating to a "hold" rating in a research report on Friday, November 1st. Truist Financial raised their price target on argenx from $540.00 to $660.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Piper Sandler upped their price objective on argenx from $553.00 to $620.00 and gave the company an "overweight" rating in a research note on Friday, November 1st. William Blair upgraded argenx from a "market perform" rating to an "outperform" rating in a research note on Friday, November 1st. Finally, Citigroup boosted their target price on argenx from $512.00 to $635.00 and gave the company a "buy" rating in a report on Thursday, October 17th.

argenx Stock Performance

NASDAQ ARGX traded up $4.50 during trading hours on Monday, hitting $628.32. The company had a trading volume of 153,614 shares, compared to its average volume of 308,013. The business has a 50 day moving average of $592.94 and a 200-day moving average of $526.12. The company has a market cap of $37.93 billion, a PE ratio of -714.00 and a beta of 0.59. argenx has a 1-year low of $349.86 and a 1-year high of $644.97.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $1.29. The firm had revenue of $588.88 million for the quarter, compared to the consensus estimate of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same quarter last year, the business posted ($1.25) EPS. Sell-side analysts expect that argenx will post 2.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On argenx

Institutional investors have recently modified their holdings of the company. Lord Abbett & CO. LLC acquired a new position in argenx during the third quarter worth approximately $88,339,000. Wilmington Savings Fund Society FSB purchased a new position in shares of argenx in the 3rd quarter worth $652,000. Sanctuary Advisors LLC boosted its holdings in argenx by 17.5% in the third quarter. Sanctuary Advisors LLC now owns 2,064 shares of the company's stock valued at $1,119,000 after acquiring an additional 308 shares during the last quarter. M&T Bank Corp grew its position in argenx by 7.2% during the third quarter. M&T Bank Corp now owns 4,307 shares of the company's stock valued at $2,335,000 after acquiring an additional 289 shares during the period. Finally, MML Investors Services LLC raised its holdings in shares of argenx by 16.9% in the 3rd quarter. MML Investors Services LLC now owns 8,699 shares of the company's stock worth $4,715,000 after purchasing an additional 1,255 shares during the period. Institutional investors and hedge funds own 60.32% of the company's stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.